| Market Cap | 3.28M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -1.69M | Forward P/E | -2.19 | EPS next Y | - | 50D Avg Chg | -34.00% |
| Sales | 76.76k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -78.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -89.00% |
| Recommedations | - | Quick Ratio | 0.06 | Shares Outstanding | 1.50M | 52W Low Chg | 119.00% |
| Insider Own | 44.14% | ROA | -148.50% | Shares Float | 806.79K | Beta | 2.77 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | 191/293 | Price | 0.02 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 174,977 | Target Price | - |
| Oper. Margin | -1,588.91% | Earnings Date | - | Volume | 22,600 | Change | -4.78% |
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.